Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Status:
Completed
Trial end date:
2019-10-25
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial studies the side effects and best dose of azacitidine and sonidegib or
decitabine and so see how well they work in treating patients with myeloid malignancies. The
hedgehog (Hh) signaling pathway plays an important role in cellular growth, differentiation
and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular
proliferation may be associated with mutations in the Hh-ligand cell surface receptor Smo.
Sonidegib binds to the Hh cell surface receptor Smo, which may result in the suppression of
the Hh signaling pathway and the inhibition of cancer cells. Azacitidine and decitabine may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving azacitidine together with sonidegib or decitabine may be a safe and successful
treatment for patients with myeloid malignancies.